• 1
    Staeva-Vieira T, Peakman M, von Herrath M. Translational mini-review series on type 1 diabetes: immune-based therapeutic approaches for type 1 diabetes. Clin Exp Immunol 2007; 148:1731.
  • 2
    Herold KC, Hagopian W, Auger JA et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346:16921698.
  • 3
    Keymeulen B, Vandemeulebroucke E, Ziegler AG et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352:25982608.
  • 4
    Matthews JB, Staeva TP, Bernstein PL, Peakman M, von Herrath M. Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN–JDRF Type 1 Diabetes Combination Therapy Assessment Group. Clin Exp Immunol 2010; 160:176184.
  • 5
    Roep BO, Peakman M. Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetes. Nat Rev Immunol 2010; 10:145152.
  • 6
    Coppieters KT, Dotta F, Amirian N et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med 2012; 209:5160.
  • 7
    Ahmed S, Akirav E, Bradshaw EM et al. Immunologic biomarkers: catalysts for translational advances in autoimmune diabetes. Clin Exp Immunol 2013; 172:178185.
  • 8
    Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009; 361:21432152.
  • 9
    Keymeulen B, Walter M, Mathieu C et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 2010; 53:614623.
  • 10
    Campbell-Thompson M, Wasserfall C, Kaddis J et al. Network for Pancreatic Organ Donors with Diabetes (nPOD): developing a tissue biobank for type 1 diabetes. Diabetes Metab Res Rev 2012; 28:608617.
  • 11
    Meier JJ, Bhushan A, Butler AE, Rizza RA, Butler PC. Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? Diabetologia 2005; 48:22212228.
  • 12
    Ludvigsson J, Krisky D, Casas R et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med 2012; 366:433442.
  • 13
    Sherry N, Hagopian W, Ludvigsson J et al. Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011; 378:487497.
  • 14
    Orban T, Bundy B, Becker DJ et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 378:412419.
  • 15
    Skyler JS, Krischer JP, Wolfsdorf J et al. Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial – Type 1. Diabetes Care 2005; 28:10681076.
  • 16
    Thrower SL, James L, Hall W et al. Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study. Clin Exp Immunol 2009; 155:156165.
  • 17
    Huurman VA, van der Torren CR, Gillard P et al. Immune responses against islet allografts during tapering of immunosuppression – a pilot study in five subjects. Clin Exp Immunol 2011; 169:190198.
  • 18
    Hilbrands R, Huurman VA, Gillard P et al. Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients. Diabetes 2009; 58:22672276.
  • 19
    Huurman VA, Hilbrands R, Pinkse GG et al. Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation. PLoS ONE 2008; 3:e2435.
  • 20
    Long SA, Rieck M, Sanda S et al., Diabetes TrialNet and the Immune Tolerance Network. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs beta-cell function. Diabetes 2012; 61:23402348.
  • 21
    Pescovitz MD, Torgerson TR, Ochs HD et al. Type 1 Diabetes TrialNet Study G. Effect of rituximab on human in vivo antibody immune responses. J Allergy Clin Immunol 2011; 128:12951302.
  • 22
    Gitelman SE, Fisher LK, Gottlieb PA et al., START Study Team. Effect of anti-thymocyte globulin (ATG) on preserving beta cell function in new-onset type 1 diabetes. Poster Presentation 454, European Association for the Study of Diabetes, 2012.
  • 23
    Viglietta V, Kent SC, Orban T, Hafler DA. GAD65-reactive T cells are activated in patients with autoimmune type 1a diabetes. J Clin Invest 2002; 109:895903.
  • 24
    Mastrandrea L, Yu J, Behrens T et al. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care 2009; 32:12441249.
  • 25
    Moran A, Bundy B, Becker DJ et al., Group AS. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicenter, randomized double-masked, placebo-controlled trials. Lancet 2013; in press.
  • 26
    Ablamunits V, Henegariu O, Hansen JB et al. Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation. Diabetes 2012; 61:145154.
  • 27
    Tree TI, Lawson J, Edwards H et al. Naturally arising human CD4 T-cells that recognize islet autoantigens and secrete interleukin-10 regulate proinflammatory T-cell responses via linked suppression. Diabetes 2010; 59:14511460.
  • 28
    Nanto-Salonen K, Kupila A, Simell S et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 2008; 372:17461755.
  • 29
    Ludvigsson J, Faresjo M, Hjorth M et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008; 359:19091920.
  • 30
    Wherrett DK, Bundy B, Becker DJ et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 2011; 378:319327.
  • 31
    Orban T, Farkas K, Jalahej H et al. Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J Autoimmun 2010; 34:408415.
  • 32
    Bresson D, Togher L, Rodrigo E et al. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest 2006; 116:13711381.
  • 33
    Takiishi T, Korf H, Van Belle TL et al. Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. J Clin Invest 2012; 122:17171725.
  • 34
    Kaufman DL, Clare-Salzler M, Tian J et al. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 1993; 366:6972.
  • 35
    Tisch R, Yang XD, Singer SM, Liblau RS, Fugger L, McDevitt HO. Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 1993; 366:7275.
  • 36
    Bresson D, Fradkin M, Manenkova Y, Rottembourg D, von Herrath M. Genetic-induced variations in the GAD65 T-cell repertoire governs efficacy of anti-CD3/GAD65 combination therapy in new-onset type 1 diabetes. Mol Ther 2010; 18:307316.
  • 37
    Fousteri G, Chan JR, Zheng Y et al. Virtual optimization of nasal insulin therapy predicts immunization frequency to be crucial for diabetes protection. Diabetes 2010; 59:31483158.
  • 38
    Gorus FK, Balti EV, Vermeulen I et al. Screening for insulinoma antigen 2 and zinc transporter 8 autoantibodies: a cost-effective and age-independent strategy to identify rapid progressors to clinical onset among relatives of type 1 diabetic patients. Clin Exp Immunol 2013; 171:8290.
  • 39
    Gabbay MA, Sato MN, Duarte AJ, Dib SA. Serum titres of anti-glutamic acid decarboxylase-65 and anti-IA-2 autoantibodies are associated with different immunoregulatory milieu in newly diagnosed type 1 diabetes patients. Clin Exp Immunol 2012; 168:6067.
  • 40
    Curnock RM, Reed CR, Rokni S, Broadhurst JW, Bingley PJ, Williams AJ. Insulin autoantibody affinity measurement using a single concentration of unlabelled insulin competitor discriminates risk in relatives of patients with type 1 diabetes. Clin Exp Immunol 2012; 167:6772.
  • 41
    Tiberti C, Yu L, Lucantoni F et al. Detection of four diabetes specific autoantibodies in a single radioimmunoassay: an innovative high-throughput approach for autoimmune diabetes screening. Clin Exp Immunol 2011; 166:317324.
  • 42
    Peakman M, von Herrath M. Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential. Diabetes 2010; 59:20872093.
  • 43
    Hober D, Sane F, Jaidane H, Riedweg K, Goffard A, Desailloud R. Immunology in the Clinic Review Series; focus on type 1 diabetes and viruses: role of antibodies enhancing the infection with Coxsackievirus-B in the pathogenesis of type 1 diabetes. Clin Exp Immunol 2012; 168:4751.
  • 44
    Jaidane H, Sane F, Hiar R et al. Immunology in the Clinic Review Series; focus on type 1 diabetes and viruses: enterovirus, thymus and type 1 diabetes pathogenesis. Clin Exp Immunol 2012; 168:3946.
  • 45
    Lind K, Huhn MH, Flodstrom-Tullberg M. Immunology in the Clinic Review Series; focus on type 1 diabetes and viruses: the innate immune response to enteroviruses and its possible role in regulating type 1 diabetes. Clin Exp Immunol 2012; 168:3038.
  • 46
    Grieco FA, Sebastiani G, Spagnuolo I, Patti A, Dotta F. Immunology in the Clinic Review Series; focus on type 1 diabetes and viruses: how viral infections modulate beta cell function. Clin Exp Immunol 2012; 168:2429.
  • 47
    Stene LC, Rewers M. Immunology in the Clinic Review Series; focus on type 1 diabetes and viruses: the enterovirus link to type 1 diabetes: critical review of human studies. Clin Exp Immunol 2012; 168:1223.
  • 48
    Coppieters KT, Wiberg A, Tracy SM, von Herrath MG. Immunology in the Clinic Review Series: focus on type 1 diabetes and viruses: the role of viruses in type 1 diabetes: a difficult dilemma. Clin Exp Immunol 2012; 168:511.
  • 49
    Gale EA. Viruses and type 1 diabetes: ignorance acquires a better vocabulary. Clin Exp Immunol 2012; 168:14.
  • 50
    Han D, Cai X, Wen J et al. Innate and adaptive immune gene expression profiles as biomarkers in human type 1 diabetes. Clin Exp Immunol 2012; 170:131138.
  • 51
    Abreu JR, Martina S, Verrijn Stuart AA et al. CD8 T cell autoreactivity to preproinsulin epitopes with very low human leucocyte antigen class I binding affinity. Clin Exp Immunol 2012; 170:5765.
  • 52
    Coppieters KT, Amirian N, von Herrath MG. Incidental CD8 T cell reactivity against caspase-cleaved apoptotic self-antigens from ubiquitously expressed proteins in islets from prediabetic human leucocyte antigen-A2 transgenic non-obese diabetic mice. Clin Exp Immunol 2011; 165:155162.
  • 53
    Mallone R, Mannering SI, Brooks-Worrell BM et al. Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen-reactive T cell responses: position statement of the T-Cell Workshop Committee of the Immunology of Diabetes Society. Clin Exp Immunol 2011; 163:3349.
  • 54
    Bresson D, von Herrath MG. Anti-thymoglobulin (ATG) treatment does not reverse type 1 diabetes in the acute virally induced rat insulin promoter–lymphocytic choriomeningitis virus (RIP–LCMV) model. Clin Exp Immunol 2011; 163:375380.
  • 55
    Skowera A, Ellis RJ, Varela-Calvino R et al. CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J Clin Invest 2008; 118:33903402.
  • 56
    Knight RR, Kronenberg D, Zhao M et al. Human beta-cell killing by autoreactive preproinsulin-specific CD8 T cells is predominantly granule-mediated with the potency dependent upon T-cell receptor avidity. Diabetes 2013; 62:205213.
  • 57
    Kronenberg D, Knight RR, Estorninho M et al. Circulating preproinsulin signal peptide-specific CD8 T cells restricted by the susceptibility molecule HLA-A24 are expanded at onset of type 1 diabetes and kill beta-cells. Diabetes 2012; 61:17521759.
  • 58
    Greenbaum CJ, Beam CA, Boulware D et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes 2012; 61:20662073.
  • 59
    Buzzetti R, Cernea S, Petrone A et al. C-peptide response and HLA genotypes in subjects with recent-onset type 1 diabetes after immunotherapy with DiaPep277: an exploratory study. Diabetes 2011; 60:30673072.
  • 60
    Simoni Y, Diana J, Ghazarian L, Beaudoin L, Lehuen A. Therapeutic manipulation of natural killer (NK) T cells in autoimmunity: are we close to reality? Clin Exp Immunol 2013; 171:819.
  • 61
    Keller RJ, Eisenbarth GS, Jackson RA. Insulin prophylaxis in individuals at high risk of type I diabetes. Lancet 1993; 341:927928.
  • 62
    Fuchtenbusch M, Rabl W, Grassl B, Bachmann W, Standl E, Ziegler AG. Delay of type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial. Diabetologia 1998; 41:536541.
  • 63
    Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002; 346:16851691.
  • 64
    Harrison LC, Honeyman MC, Steele CE et al. Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care 2004; 27:23482355.
  • 65
    Kupila A, Sipila J, Keskinen P et al. Intranasally administered insulin intended for prevention of type 1 diabetes – a safety study in healthy adults. Diabetes Metab Res Rev 2003; 19:415420.
  • 66
    Fourlanos S, Perry C, Gellert SA et al. Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes. Diabetes 2011; 60:12371245.
  • 67
    Achenbach P, Barker J, Bonifacio E. Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization. Curr Diab Rep 2008; 8:8793.
  • 68
    Bohmer KP, Kolb H, Kuglin B et al. Linear loss of insulin secretory capacity during the last six months preceding IDDM. No effect of antiedematous therapy with ketotifen. Diabetes Care 1994; 17:138141.
  • 69
    Carel JC, Boitard C, Eisenbarth G, Bach JF, Bougneres PF. Cyclosporine delays but does not prevent clinical onset in glucose intolerant pre-type 1 diabetic children. J Autoimmun 1996; 9:739745.
  • 70
    Lampeter EF, Klinghammer A, Scherbaum WA et al. The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group. Diabetes 1998; 47:980984.
  • 71
    Gale EA, Bingley PJ, Emmett CL, Collier T. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004; 363:925931.
  • 72
    Crino A, Schiaffini R, Ciampalini P et al. A two year observational study of nicotinamide and intensive insulin therapy in patients with recent onset type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2005; 18:749754.
  • 73
    Crino A, Schiaffini R, Manfrini S et al. A randomized trial of nicotinamide and vitamin E in children with recent onset type 1 diabetes (IMDIAB IX). Eur J Endocrinol 2004; 150:719724.
  • 74
    Pozzilli P, Visalli N, Boccuni ML et al. Randomized trial comparing nicotinamide and nicotinamide plus cyclosporin in recent onset insulin-dependent diabetes (IMDIAB 1). The IMDIAB Study Group. Diabet Med 1994; 11:98104.
  • 75
    Dahlquist G, Gothefors L. The cumulative incidence of childhood diabetes mellitus in Sweden unaffected by BCG-vaccination. Diabetologia 1995; 38:873874.
  • 76
    Huppmann M, Baumgarten A, Ziegler AG, Bonifacio E. Neonatal bacille Calmette–Guérin vaccination and type 1 diabetes. Diabetes Care 2005; 28:12041206.
  • 77
    Parent ME, Siemiatycki J, Menzies R, Fritschi L, Colle E. Bacille Calmette–Guérin vaccination and incidence of IDDM in Montreal, Canada. Diabetes Care 1997; 20:767772.
  • 78
    Hummel M, Bonifacio E, Naserke HE, Ziegler AG. Elimination of dietary gluten does not reduce titers of type 1 diabetes-associated autoantibodies in high-risk subjects. Diabetes Care 2002; 25:11111116.
  • 79
    Wicklow BA, Taback SP. Feasibility of a type 1 diabetes primary prevention trial using 2000 IU vitamin D3 in infants from the general population with increased HLA-associated risk. Ann NY Acad Sci 2006; 1079:310312.
  • 80
    Akerblom HK, Virtanen SM, Ilonen J et al. Dietary manipulation of beta cell autoimmunity in infants at increased risk of type 1 diabetes: a pilot study. Diabetologia 2005; 48:829837.
  • 81
    Knip M, Virtanen SM, Seppa K et al. Dietary intervention in infancy and later signs of beta-cell autoimmunity. N Engl J Med 2010; 363:19001908.
  • 82
    Miller MR, Seifert J, Szabo NJ, Clare-Salzler M, Rewers M, Norris JM. Erythrocyte membrane fatty acid content in infants consuming formulas supplemented with docosahexaenoic acid (DHA) and arachidonic acid (ARA): an observational study. Matern Child Nutr 2010; 6:338346.
  • 83
    Miller MR, Yin X, Seifert J et al. Erythrocyte membrane omega-3 fatty acid levels and omega-3 fatty acid intake are not associated with conversion to type 1 diabetes in children with islet autoimmunity: the Diabetes Autoimmunity Study in the Young (DAISY). Pediatr Diabetes 2011; 12:669675.
  • 84
    Vaarala O, Ilonen J, Ruohtula T et al. Removal of bovine insulin from cow's milk formula and early initiation of beta-cell autoimmunity in the FINDIA pilot study. Arch Pediatr Adolesc Med 2012; 166:608614.
  • 85
    Hummel S, Pfluger M, Hummel M, Bonifacio E, Ziegler AG. Primary dietary intervention study to reduce the risk of islet autoimmunity in children at increased risk for type 1 diabetes: the BABYDIET study. Diabetes Care 2011; 34:13011305.
  • 86
    Alleva DG, Maki RA, Putnam AL et al. Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope. Scand J Immunol 2006; 63:5969.
  • 87
    Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, Phase II trial. Lancet 2001; 358:17491753.
  • 88
    Lazar L, Ofan R, Weintrob N et al. Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind Phase II study. Diabetes Metab Res Rev 2006; 23:286291.
  • 89
    Agardh CD, Cilio CM, Lethagen A et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 2005; 19:238246.
  • 90
    Peakman M, Stevens EJ, Lohmann T et al. Naturally processed and presented epitopes of the islet cell autoantigen IA-2 eluted from HLA-DR4. J Clin Invest 1999; 104:14491457.
  • 91
    Bougneres PF, Landais P, Boisson C et al. Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Diabetes 1990; 39:12641272.
  • 92
    Jenner M, Bradish G, Stiller C, Atkison P. Cyclosporin A treatment of young children with newly-diagnosed type 1 (insulin-dependent) diabetes mellitus. London Diabetes Study Group. Diabetologia 1992; 35:884888.
  • 93
    Elliott RB, Chase HP. Prevention or delay of type 1 (insulin-dependent) diabetes mellitus in children using nicotinamide. Diabetologia 1991; 34:362365.
  • 94
    Eisenbarth GS, Srikanta S, Jackson R et al. Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. Diabetes Res 1985; 2:271276.
  • 95
    Allen HF, Klingensmith GJ, Jensen P, Simoes E, Hayward A, Chase HP. Effect of bacillus Calmette–Guérin vaccination on new-onset type 1 diabetes. A randomized clinical study. Diabetes Care 1999; 22:17031707.
  • 96
    Elliott JF, Marlin KL, Couch RM. Effect of bacille Calmette–Guérin vaccination on C-peptide secretion in children newly diagnosed with IDDM. Diabetes Care 1998; 21:16911693.
  • 97
    Shehadeh N, Calcinaro F, Bradley BJ, Bruchim I, Vardi P, Lafferty KJ. Effect of adjuvant therapy on development of diabetes in mouse and man. Lancet 1994; 343:706707.
  • 98
    Bjork E, Berne C, Kampe O, Wibell L, Oskarsson P, Karlsson FA. Diazoxide treatment at onset preserves residual insulin secretion in adults with autoimmune diabetes. Diabetes 1996; 45:14271430.
  • 99
    Ortqvist E, Bjork E, Wallensteen M et al. Temporary preservation of beta-cell function by diazoxide treatment in childhood type 1 diabetes. Diabetes Care 2004; 27:21912197.
  • 100
    Brod SA, Atkinson M, Lavis VR et al. Ingested IFN-alpha preserves residual beta cell function in type 1 diabetes. J Interferon Cytokine Res 2001; 21:10211030.
  • 101
    Kempf K, Manzo G, Hanifi-Moghaddam P et al. Effect of combined oral proteases and flavonoid treatment in subjects at risk of Type 1 diabetes. Diabet Med 2009; 26:13091310.
  • 102
    Herold KC, Gitelman SE, Willi SM et al. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia 2013; 56:391400.
  • 103
    Haller MJ, Wasserfall CH, Hulme MA et al. Autologous umbilical cord blood transfusion in young children with type 1 diabetes fails to preserve C-peptide. Diabetes Care 2011; 34:25672569.
  • 104
    Haller MJ, Wasserfall CH, McGrail KM et al. Autologous umbilical cord blood transfusion in very young children with type 1 diabetes. Diabetes Care 2009; 32:20412046.
  • 105
    Saudek F, Havrdova T, Boucek P, Karasova L, Novota P, Skibova J. Polyclonal anti-T-cell therapy for type 1 diabetes mellitus of recent onset. Rev Diabet Stud 2004; 1:8088.
  • 106
    Giannoukakis N, Phillips B, Finegold D, Harnaha J, Trucco M. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care 2011; 34:20262032.
  • 107
    Sumpter KM, Adhikari S, Grishman EK, White PC. Preliminary studies related to anti-interleukin-1beta therapy in children with newly diagnosed type 1 diabetes. Pediatr Diabetes 2011; 12:656667.
  • 108
    Mandrup-Poulsen T. IL-1 receptor antagonist in recent onset type 1 diabetes- a multicentre randomized, placedbo controlled trial [IT-SYO1]. Presented at: 72nd Scientific Session of the American Diabetes Association; 11 June 2012; Philadephia, PA.
  • 109
    Moran A. Canakinumab, an anti-IL-1 monoclonal antibody in recent -onset type 1 diabetes [IT-SY01]. Presented at: 72nd Scientific Session of the American Diabetes Association; 11 June 2012; Philadelphia, PA.
  • 110
    Walter M, Kaupper T, Adler K, Foersch J, Bonifacio E, Ziegler AG. No effect of the 1alpha,25-dihydroxyvitamin D3 on beta-cell residual function and insulin requirement in adults with new-onset type 1 diabetes. Diabetes Care 2010; 33:14431448.
  • 111
    Gu W, Hu J, Wang W et al. Diabetic ketoacidosis at diagnosis influences complete remission after treatment with hematopoietic stem cell transplantation in adolescents with type 1 diabetes. Diabetes Care 2012; 35:14131419.
  • 112
    Strom A, Kolb H, Martin S et al. Improved preservation of residual beta cell function by atorvastatin in patients with recent onset type 1 diabetes and high CRP levels (DIATOR trial). PLoS ONE 2012; 7:e33108.
  • 113
    Martin S, Herder C, Schloot NC et al. Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the Randomized DIATOR Trial. PLoS ONE 2011; 6:e17554.
  • 114
    Rother KI, Brown RJ, Morales MM et al. Effect of ingested interferon-alpha on beta-cell function in children with new-onset type 1 diabetes. Diabetes Care 2009; 32:12501255.
  • 115
    Faustman DL, Wang L, Okubo Y et al. Proof-of-concept, randomized, controlled clinical trial of bacillus-Calmette–Guérin for treatment of long-term type 1 diabetes. PLoS ONE 2012; 7:e41756.
  • 116
    Gottlieb PA, Quinlan S, Krause-Steinrauf H et al. Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new-onset type 1 diabetes. Diabetes Care 2010; 33:826832.
  • 117
    Couri CE, Oliveira MC, Stracieri AB et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2009; 301:15731579.
  • 118
    Voltarelli JC, Couri CE, Stracieri AB et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2007; 297:15681576.
  • 119
    Barcala Tabarrozzi AE, Castro CN, Dewey RA, Sogayar MC, Labriola L, Perone MJ. Cell-based interventions to halt autoimmunity in type 1 diabetes mellitus. Clin Exp Immunol 2013; 171:135146.
  • 120
    de Oliveira GL, Malmegrim KC, Ferreira AF et al. Up-regulation of fas and fasL pro-apoptotic genes expression in type 1 diabetes patients after autologous haematopoietic stem cell transplantation. Clin Exp Immunol 2012; 168:291302.